Area of interest: Drug Development

  • Gesynta Pharma raises 26.5 MEUR

    Gesynta Pharma raises 26.5 MEUR

    (Stockholm, is developing a drug candidate for the treatment of endometriosis): Has raised 26.5 MEUR in a funding round led by Innovestor Life Science, with participation from Hadean Ventures, Linc, Foreground Capital, Catalyze Capital, Stephen Industries, Amboy Street Ventures, and Industrifonden with member Peter Wolpert. The funding will support a Phase II clinical trial in Europe.

  • AnaCardio raises 19 MUSD

    AnaCardio raises 19 MUSD

    (Stockholm, develops novel drugs to treat heart failure): Has raised 19 MUSD in a funding round from Novo Holdings, Pureos Bioventures, Sound Bioventures, Flerie, Fredrik andAnn-Helene Ljungström alongside Industrifonden with member Peter Wolpert. “We now have the data and funding to accelerate the further clinical development of our first-in-class inotrope to improve the lives of patients with heart failure,” comments…